Gelonghui, May 30丨Fuxiang Pharmaceutical (300497.SZ) announced that currently, since Ling Kai Pharmaceutical is planning an initial public offering and listing plan on the Hong Kong Stock Exchange Limited, in order to comply with the regulations and requirements of laws and regulations, the Hong Kong Stock Exchange, the Hong Kong Securities and Futures Commission, the China Securities Regulatory Commission, etc., the parties agreed to terminate the performance compensation, repurchase rights, and shareholder special “Shareholders' Agreement” on the day before the date Ling Kai Pharmaceutical first submitted the listing application form to the Hong Kong Stock Exchange Any agreement or arrangement on “performance compensation rights” and “repurchase rights” reached before the signing of the “Rights Termination Agreement”, and agrees that if the rights and obligations between shareholders and/or shareholders relating to shareholders' rights enjoyed by shareholders after the target company's overseas listing (including but not limited to share transfer restrictions, anti-dilution protection rights, equal treatment clauses, right to know, competition restrictions, etc.) agreed upon in the “Capital Increase Agreement” and the “Shanghai Lingkai Pharmaceutical Technology Co., Ltd. Constitution” applied by the target company after it was first issued and listed on the Hong Kong Stock Exchange and other internal systems passed by the shareholders' meeting or not Complying with the relevant rules and regulatory requirements applicable by other regulators, they shall be terminated from the date the target company's shares are listed on the Hong Kong Stock Exchange.

However, if any of the following circumstances occur after Ling Kai Pharmaceutical first submitted the listing application form to the Hong Kong Stock Exchange, the “Shareholders' Special Rights Termination Agreement” shall automatically terminate and be null and void from the date of occurrence of the following circumstances. The “Capital Increase Agreement” and the “Shareholder Agreement” shall automatically return to the state before the “Termination Agreement on Shareholders' Special Rights” was signed, and are deemed effective from the beginning: (1) The target company voluntarily withdraws the listing application; (2) The Hong Kong Stock Exchange, the Hong Kong Securities and Futures Commission or other securities regulators disagree with the target company's listing application or rejection Rejected listing Applications and other decisions to terminate the listing review process; (3) The target company did not complete the Hong Kong stock listing within 12 months from the date of approval of the Hong Kong Stock Exchange hearing for any reason.